{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:20:55Z","timestamp":1747207255508,"version":"3.40.5"},"reference-count":231,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MIRNA"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Cancer, the second greatest cause of mortality worldwide, frequently causes bone metastases\nin patients with advanced-stage carcinomas such as prostate, breast, and lung cancer. The\nexistence of these metastases contributes to the occurrence of skeletal-related events (SREs),\nwhich are defined by excessive pain, pathological fractures, hypercalcemia, and spinal cord compression.\nThese injurious incidents leave uncomfortably in each of the cancer patient\u2019s life quality.\nPrimary bone cancers, including osteosarcoma (OS), chondrosarcoma (CS), and Ewing's sarcoma\n(ES), have unclear origins. MicroRNA (miRNA) expression patterns have been changed in\nprimary bone cancers such as OS, CS, and ES, indicating a role in tumor development, invasion,\nmetastasis, and treatment response. These miRNAs are persistent in circulation and exhibit distinct\npatterns in many forms of bone tumors, making them potential biomarkers for early detection\nand treatment of such diseases. Given their crucial regulatory functions in various biological processes\nand conditions, including cancer, this study aims to look at miRNAs' activities and possible\ncontributions to bone malignancies, focusing on OS, CS, and ES. In conclusion, miRNAs are\nvaluable tools for diagnosing, monitoring, and predicting OS, CS, and ES outcomes. Further research\nis required to fully comprehend the intricate involvement of miRNAs in these bone cancers\nand to develop effective miRNA-based treatments.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0122115366298799240625115843","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T08:02:03Z","timestamp":1721030523000},"page":"175-201","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Landscape of microRNAs in Bone Tumor: A Comprehensive Review in Recent Studies"],"prefix":"10.2174","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6162-8446","authenticated-orcid":true,"given":"Ramin","family":"Raoufinia","sequence":"first","affiliation":[{"name":"Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran"},{"name":"Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parisa","family":"Afrasiabi","sequence":"additional","affiliation":[{"name":"Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Dehghanpour","sequence":"additional","affiliation":[{"name":"Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Memarpour","sequence":"additional","affiliation":[{"name":"Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayyed Hadi Sayyed","family":"Hosseinian","sequence":"additional","affiliation":[{"name":"Orthopedic Research Center, Shahid Kamyab Hospital, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehsan","family":"Saburi","sequence":"additional","affiliation":[{"name":"Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Naghipoor","sequence":"additional","affiliation":[{"name":"Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samaneh","family":"Rezaei","sequence":"additional","affiliation":[{"name":"Vascular and Endovascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meisam","family":"Haghmoradi","sequence":"additional","affiliation":[{"name":"Orthopedic Research Center, Shahid Kamyab Hospital, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neda","family":"Keyhanvar","sequence":"additional","affiliation":[{"name":"Department of Biochemistry &amp; Biophysics, University of California San Francisco, San Francisco, CA, 94107, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Rostami","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Fakoor","sequence":"additional","affiliation":[{"name":"Department of Paramedical Sciences, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadali Izadpanah","family":"Kazemi","sequence":"additional","affiliation":[{"name":"Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meysam","family":"Moghbeli","sequence":"additional","affiliation":[{"name":"Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2269-4109","authenticated-orcid":true,"given":"Hamid Reza","family":"Rahimi","sequence":"additional","affiliation":[{"name":"Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"},{"name":"Vascular and Endovascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"205","volume":"98","author":"Ferguson J.L.","year":"2018","unstructured":"Ferguson J.L.; Turner S.P.; Bone cancer: Diagnosis and treatment principles. Am Fam Physician  2018,98(4),205-213","journal-title":"Am Fam Physician"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1007\/s10278-017-0001-7","volume":"30","author":"Do B.H.","year":"2017","unstructured":"Do B.H.; Langlotz C.; Beaulieu C.F.; Bone tumor diagnosis using a na\u00efve Bayesian model of demographic and radiographic features. J Digit Imaging  2017,30(5),640-647","journal-title":"J Digit Imaging"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"e28352","DOI":"10.1002\/pbc.28352","volume":"68","author":"Eaton B.R.","year":"2021","unstructured":"Eaton B.R.; Schwarz R.; Vatner R.; Osteosarcoma. Pediatr Blood Cancer  2021,68(S2),e28352","journal-title":"Pediatr Blood Cancer"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41572-022-00409-y","volume":"8","author":"Beird H.C.","year":"2022","unstructured":"Beird H.C.; Bielack S.S.; Flanagan A.M.; Osteosarcoma. Nat Rev Dis Primers  2022,8(1),77","journal-title":"Nat Rev Dis Primers"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-018-0003-x","volume":"4","author":"Gr\u00fcnewald T.G.P.","year":"2018","unstructured":"Gr\u00fcnewald T.G.P.; Cidre-Aranaz F.; Surdez D.; Ewing sarcoma. Nat Rev Dis Primers  2018,4(1),5","journal-title":"Nat Rev Dis Primers"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PAP.0000000000000293","volume":"28","author":"Choi J.H.","year":"2021","unstructured":"Choi J.H.; Ro J.Y.; The 2020 WHO classification of tumors of bone: An updated review. Adv Anat Pathol  2021,28(3),119-138","journal-title":"Adv Anat Pathol"},{"key":"ref=7","first-page":"553","volume":"29","author":"Weinschenk R.C.","year":"2021","unstructured":"Weinschenk R.C.; Wang W-L.; Lewis V.O.; Chondrosarcoma. JAAOS  2021,29(13),553-562","journal-title":"JAAOS"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1007\/s12094-022-02784-0","volume":"24","author":"Orcajo-Rincon J.","year":"2022","unstructured":"Orcajo-Rincon J.; Mu\u00f1oz-Langa J.; Sep\u00falveda-S\u00e1nchez J.M.; Review of imaging techniques for evaluating morphological and functional responses to the treatment of bone metastases in prostate and breast cancer. Clin Transl Oncol  2022,24(7),1290-1310","journal-title":"Clin Transl Oncol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"Coleman R.E.","year":"2006","unstructured":"Coleman R.E.; Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res  2006,12(20),6243s-6249s","journal-title":"Clin Cancer Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3233\/BD-2007-26108","volume":"26","author":"Allan AL","year":"2007-2007","unstructured":"Allan AL; Vantyghem SA; Tuck AB; Chambers AF; Tumor dormancy and cancer stem cells: Implications for the biology and treatment of breast cancer metastasis. Breast Dis  2007-2007,26(1),87-98","journal-title":"Breast Dis"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"Roodman G.D.","year":"2004","unstructured":"Roodman G.D.; Mechanisms of bone metastasis. N Engl J Med  2004,350(16),1655-1664","journal-title":"N Engl J Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/S0305-7372(10)70013-X","volume":"36","author":"Santini D.","year":"2010","unstructured":"Santini D.; Galluzzo S.; Zoccoli A.; New molecular targets in bone metastases. Cancer Treat Rev  2010,36,S6-S10","journal-title":"Cancer Treat Rev"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bone.2010.10.161","volume":"48","author":"Lipton A.","year":"2011","unstructured":"Lipton A.; Goessl C.; Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis. Bone  2011,48(1),96-99","journal-title":"Bone"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/B978-0-323-47674-4.00056-6","author":"Coleman R.E.","year":"2020","unstructured":"Coleman R.E.; Brown J.; Holen I.; Bone metastases. In: Abeloff's Clinical Oncology.  2020,809-830.e3"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.4329\/wjr.v7.i8.202","volume":"7","author":"O\u2019Sullivan G.J.","year":"2015","unstructured":"O\u2019Sullivan G.J.; Carty F.L.; Cronin C.G.; Imaging of bone metastasis: An update. World J Radiol  2015,7(8),202-211","journal-title":"World J Radiol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.5114\/wo.2017.68617","volume":"21","author":"\u0141ukaszewski B.","year":"2017","unstructured":"\u0141ukaszewski B.; Nazar J.; Goch M.; \u0141ukaszewska M.; St\u0119pi\u0144ski A.; Jurczyk M.U.; Diagnostic methods for detection of bone metastases. Contemp Oncol (Pozn)  2017,21(2),98-103","journal-title":"Contemp Oncol (Pozn)"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10195-015-0344-0","volume":"16","author":"Piccioli A.","year":"2015","unstructured":"Piccioli A.; Maccauro G.; Spinelli M.S.; Biagini R.; Rossi B.; Bone metastases of unknown origin: Epidemiology and principles of management. J Orthop Traumatol  2015,16(2),81-86","journal-title":"J Orthop Traumatol"},{"key":"ref=18","first-page":"53","volume":"45","author":"Rybak L.D.","year":"2001","unstructured":"Rybak L.D.; Rosenthal D.I.; Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med  2001,45(1),53-64","journal-title":"Q J Nucl Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/978-1-4419-0284-9_4","volume":"152","author":"Raymond A.K.","year":"2009","unstructured":"Raymond A.K.; Jaffe N.; Osteosarcoma multidisciplinary approach to the management from the pathologist\u2019s perspective. Cancer Treat Res  2009,152,63-84","journal-title":"Cancer Treat Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","volume":"33","author":"Isakoff M.S.","year":"2015","unstructured":"Isakoff M.S.; Bielack S.S.; Meltzer P.; Gorlick R.; Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol  2015,33(27),3029-3035","journal-title":"J Clin Oncol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12938-021-00860-0","volume":"20","author":"Zhao X.","year":"2021","unstructured":"Zhao X.; Wu Q.; Gong X.; Liu J.; Ma Y.; Osteosarcoma: A review of current and future therapeutic approaches. Biomed Eng Online  2021,20(1),24","journal-title":"Biomed Eng Online"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10585-011-9384-x","volume":"28","year":"2011","unstructured":"Witlox MA, Kaspers GJL, van Royen BJ. Molecular alterations as target for therapy in metastatic osteosarcoma: A review of literature. Clin Exp Metastasis PosthumaDeBoer J 2011,28(5),493-503","journal-title":"Clin Exp Metastasis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/ijc.24320","volume":"125","author":"Mirabello L.","year":"2009","unstructured":"Mirabello L.; Troisi R.J.; Savage S.A.; International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer  2009,125(1),229-234","journal-title":"Int J Cancer"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/cncr.24121","volume":"115","author":"Mirabello L.","year":"2009","unstructured":"Mirabello L.; Troisi R.J.; Savage S.A.; Osteosarcoma incidence and survival rates from 1973 to 2004. Cancer  2009,115(7),1531-1543","journal-title":"Cancer"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.3390\/cancers12082130","volume":"12","author":"Czarnecka A.M.","year":"2020","unstructured":"Czarnecka A.M.; Synoradzki K.; Firlej W.; Molecular biology of osteosarcoma. Cancers (Basel)  2020,12(8),2130","journal-title":"Cancers (Basel)"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bone.2016.10.017","volume":"102","author":"Rickel K.","year":"2017","unstructured":"Rickel K.; Fang F.; Tao J.; Molecular genetics of osteosarcoma. Bone  2017,102,69-79","journal-title":"Bone"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ocl.2015.08.022","volume":"47","author":"Anderson M.E.","year":"2016","unstructured":"Anderson M.E.; Update on survival in osteosarcoma. Orthop Clin North Am  2016,47(1),283-292","journal-title":"Orthop Clin North Am"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.12688\/f1000research.9465.1","volume":"5","author":"Bielack S.S.","year":"2016","unstructured":"Bielack S.S.; Hecker-Nolting S.; Blattmann C.; Kager L.; Advances in the management of osteosarcoma. F1000 Res  2016,5,2767","journal-title":"F1000 Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2106\/JBJS.K.00971","volume":"94","author":"Jones K.B.","year":"2012","unstructured":"Jones K.B.; Ferguson P.C.; Lam B.; Effects of neoadjuvant chemotherapy on image-directed planning of surgical resection for distal femoral osteosarcoma. J Bone Joint Surg Am  2012,94(15),1399-1405","journal-title":"J Bone Joint Surg Am"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"8214","DOI":"10.3390\/ijms22158214","volume":"22","author":"Ambrosio L.","year":"2021","unstructured":"Ambrosio L.; Raucci M.G.; Vadal\u00e0 G.; Ambrosio L.; Papalia R.; Denaro V.; Innovative biomaterials for the treatment of bone cancer. Int J Mol Sci  2021,22(15),8214","journal-title":"Int J Mol Sci"},{"key":"ref=31","author":"Lanzkowsky P.","year":"2005","unstructured":"Lanzkowsky P.;  Manual of pediatric hematology and oncology  2005","journal-title":"Manual of pediatric hematology and oncology"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/cncr.30589","volume":"123","author":"Reed D.R.","year":"2017","unstructured":"Reed D.R.; Hayashi M.; Wagner L.; Treatment pathway of bone sarcoma in children, adolescents, and young adults. Cancer  2017,123(12),2206-2218","journal-title":"Cancer"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/PAT.0000000000000050","volume":"46","author":"Jo V.Y.","year":"2014","unstructured":"Jo V.Y.; Fletcher C.D.M.; WHO classification of soft tissue tumours: An update based on the 2013 (4th) edition. Pathology  2014,46(2),95-104","journal-title":"Pathology"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.suronc.2018.05.009","volume":"27","author":"van Praag Veroniek V.M.","year":"2018","unstructured":"van Praag Veroniek V.M.; Rueten-Budde A.J.; Ho V.; Dijkstra P.D.S.; Fiocco M.; van de Sande M.A.J.; Incidence, outcomes and prognostic factors during 25 years of treatment of chondrosarcomas. Surg Oncol  2018,27(3),402-408","journal-title":"Surg Oncol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1302\/1863-2548.13.180109","volume":"13","author":"Wu A.M.","year":"2019","unstructured":"Wu A.M.; Li G.; Zheng J.W.; Chondrosarcoma in a paediatric population: A study of 247 cases. J Child Orthop  2019,13(1),89-99","journal-title":"J Child Orthop"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3941\/jrcr.v6i12.1241","volume":"6","author":"Mosier A.D.","year":"2012","unstructured":"Mosier A.D.; Mosier S.M.; Strenge K.; Patel T.; Chondrosarcoma in childhood: The radiologic and clinical conundrum. J Radiol Case Rep  2012,6(12),32-42","journal-title":"J Radiol Case Rep"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.3390\/cancers12071962","volume":"12","author":"Monga V.","year":"2020","unstructured":"Monga V.; Mani H.; Hirbe A.; Milhem M.; Non-conventional treatments for conventional chondrosarcoma. Cancers (Basel)  2020,12(7),1962","journal-title":"Cancers (Basel)"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.critrevonc.2018.09.001","volume":"131","author":"Nazeri E.","year":"2018","unstructured":"Nazeri E.; Gouran Savadkoohi M.; Majidzadeh-A K.; Esmaeili R.; Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets. Crit Rev Oncol Hematol  2018,131,102-109","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1002\/cncr.23978","volume":"113","author":"Drilon A.D.","year":"2008","unstructured":"Drilon A.D.; Popat S.; Bhuchar G.; Extraskeletal myxoid chondrosarcoma. Cancer  2008,113(12),3364-3371","journal-title":"Cancer"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/359162a0","volume":"359","author":"Delattre O.","year":"1992","unstructured":"Delattre O.; Zucman J.; Plougastel B.; Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature  1992,359(6391),162-165","journal-title":"Nature"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.3390\/jcm10081685","volume":"10","author":"Z\u00f6llner S.K.","year":"2021","unstructured":"Z\u00f6llner S.K.; Amatruda J.F.; Bauer S.; Ewing sarcoma\u2014diagnosis, treatment, clinical challenges and future perspectives. J Clin Med  2021,10(8),1685","journal-title":"J Clin Med"},{"journal-title":"In: PDQ Cancer Information Summaries Bethesda (MD): National Cancer Institute (US)","year":"2002","key":"ref=42","unstructured":"Ewing Sarcoma and Undifferentiated Small Round Cell Sarcomas of Bone and Soft Tissue Treatment (PDQ\u00ae): Health Professional Version. In: PDQ Cancer Information Summaries Bethesda (MD): National Cancer Institute (US) PDQ Pediatric Treatment Editorial Board 2002"},{"key":"ref=43","unstructured":"Ewing Sarcoma and Undifferentiated Small Round Cell Sarcomas of Bone and Soft Tissue Treatment (PDQ\u00ae), Health Professional Version, NCI (cancer.gov).  Available from:  https:\/\/www.cancer.gov\/publications\/pdq"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1002\/hed.26089","volume":"42","author":"Yoon A.J.","year":"2020","unstructured":"Yoon A.J.; Wang S.; Kutler D.I.; MicroRNA\u2010based risk scoring system to identify early\u2010stage oral squamous cell carcinoma patients at high\u2010risk for cancer\u2010specific mortality. Head Neck  2020,42(8),1699-1712","journal-title":"Head Neck"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/jbm.a.36824","volume":"108","author":"Tahmasebi A.","year":"2020","unstructured":"Tahmasebi A.; Enderami S.E.; Saburi E.; Micro\u2010RNA\u2010incorporated electrospun nanofibers improve osteogenic differentiation of human\u2010induced pluripotent stem cells. J Biomed Mater Res A  2020,108(2),377-386","journal-title":"J Biomed Mater Res A"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1002\/pat.4946","volume":"31","author":"Abazari M.F.","year":"2020","unstructured":"Abazari M.F.; Zare Karizi S.; Kohandani M.; MicroRNA-2861 and nanofibrous scaffold synergistically promote human induced pluripotent stem cells osteogenic differentiation. Polym Adv Technol  2020,31(10),2259-2269","journal-title":"Polym Adv Technol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"dmm047662","DOI":"10.1242\/dmm.047662","volume":"14","author":"Hill M.","year":"2021","unstructured":"Hill M.; Tran N.; miRNA interplay: Mechanisms and consequences in cancer. Dis Model Mech  2021,14(4),dmm047662","journal-title":"Dis Model Mech"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature03120","volume":"432","author":"Gregory R.I.","year":"2004","unstructured":"Gregory R.I.; Yan K.; Amuthan G.; The microprocessor complex mediates the genesis of microRNAs. Nature  2004,432(7014),235-240","journal-title":"Nature"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.cell.2015.05.010","volume":"161","author":"Nguyen T.A.","year":"2015","unstructured":"Nguyen T.A.; Jo M.H.; Choi Y.G.; Functional anatomy of the human microprocessor. Cell  2015,161(6),1374-1387","journal-title":"Cell"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/ng865","volume":"30","author":"Lai E.C.","year":"2002","unstructured":"Lai E.C.; Micro RNAs are complementary to 3\u2032 UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet  2002,30(4),363-364","journal-title":"Nat Genet"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1146\/annurev-pathol-012513-104715","volume":"9","author":"Di Leva G.","year":"2014","unstructured":"Di Leva G.; Garofalo M.; Croce C.M.; MicroRNAs in cancer. Annu Rev Pathol  2014,9(1),287-314","journal-title":"Annu Rev Pathol"},{"key":"ref=52","first-page":"2735","volume":"15","author":"Tan W.","year":"2018","unstructured":"Tan W.; Liu B.; Qu S.; Liang G.; Luo W.; Gong C.; MicroRNAs and cancer: Key paradigms in molecular therapy. Oncol Lett  2018,15(3),2735-2742","journal-title":"Oncol Lett"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00109-014-1129-2","volume":"92","author":"Raza U.","year":"2014","unstructured":"Raza U.; Zhang J.D.; \u015eahin \u00d6.; MicroRNAs: Master regulators of drug resistance, stemness, and metastasis. J Mol Med (Berl)  2014,92(4),321-336","journal-title":"J Mol Med (Berl)"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"140","DOI":"10.5732\/cjc.013.10094","volume":"33","author":"Ding X.M.","year":"2014","unstructured":"Ding X.M.; MicroRNAs: Regulators of cancer metastasis and epithelial-mesenchymal transition (EMT). Chin J Cancer  2014,33(3),140-147","journal-title":"Chin J Cancer"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/hmg\/ddt569","volume":"23","author":"Spengler R.M.","year":"2014","unstructured":"Spengler R.M.; Oakley C.K.; Davidson B.L.; Functional microRNAs and target sites are created by lineage-specific transposition. Hum Mol Genet  2014,23(7),1783-1793","journal-title":"Hum Mol Genet"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.3390\/ijms23042348","volume":"23","author":"Scuderi S.A.","year":"2022","unstructured":"Scuderi S.A.; Calabrese G.; Paterniti I.; The biological function of microRNAs in bone tumors. Int J Mol Sci  2022,23(4),2348","journal-title":"Int J Mol Sci"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"17981","DOI":"10.1038\/s41598-018-36321-3","volume":"8","author":"Khalighfard S.","year":"2018","unstructured":"Khalighfard S.; Alizadeh A.M.; Irani S.; Omranipour R.; Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients. Sci Rep  2018,8(1),17981","journal-title":"Sci Rep"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s12933-023-01988-0","volume":"22","author":"Nemecz M.","year":"2023","unstructured":"Nemecz M.; Stefan D.S.; Comari\u021ba I.K.; Microvesicle-associated and circulating microRNAs in diabetic dyslipidemia: miR-218, miR-132, miR-143, and miR-21, miR-122, miR-155 have biomarker potential. Cardiovasc Diabetol  2023,22(1),260","journal-title":"Cardiovasc Diabetol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ncrna.2020.08.003","volume":"5","author":"Ahadi A.","year":"2020","unstructured":"Ahadi A.; The significance of microRNA deregulation in colorectal cancer development and the clinical uses as a diagnostic and prognostic biomarker and therapeutic agent. Noncoding RNA Res  2020,5(3),125-134","journal-title":"Noncoding RNA Res"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.3390\/ijms22094332","volume":"22","author":"Maciak K.","year":"2021","unstructured":"Maciak K.; Dziedzic A.; Miller E.; Saluk-Bijak J.; miR-155 as an important regulator of multiple sclerosis pathogenesis. A review. Int J Mol Sci  2021,22(9),4332","journal-title":"Int J Mol Sci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/biomedicines9050463","volume":"9","author":"Llobat L.","year":"2021","unstructured":"Llobat L.; Gourbault O.; Role of MicroRNAs in human osteosarcoma: Future perspectives. Biomedicines  2021,9(5),463","journal-title":"Biomedicines"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"e21902","DOI":"10.1097\/MD.0000000000021902","volume":"99","author":"Wu F.","year":"2020","unstructured":"Wu F.; Jiang X.; Wang Q.; The impact of miR-9 in osteosarcoma. Medicine (Baltimore)  2020,99(35),e21902","journal-title":"Medicine (Baltimore)"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/1477-7819-12-195","volume":"12","author":"Xu S.","year":"2014","unstructured":"Xu S.; Yang Y.; Han S.; Wu Z.; MicroRNA-9 expression is a prognostic biomarker in patients with osteosarcoma. World J Surg Oncol  2014,12(1),195","journal-title":"World J Surg Oncol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1177\/0300060514534643","volume":"42","author":"Fei D.","year":"2014","unstructured":"Fei D.; Li Y.; Zhao D.; Zhao K.; Dai L.; Gao Z.; Serum miR-9 as a prognostic biomarker in patients with osteosarcoma. J Int Med Res  2014,42(4),932-937","journal-title":"J Int Med Res"},{"key":"ref=65","first-page":"218","volume":"20","author":"Gang W.","year":"2020","unstructured":"Gang W.; Tanjun W.; Yong H.; Jiajun Q.; Yi Z.; Hao H.; Inhibition of miR-9 decreases osteosarcoma cell proliferation. Bosn J Basic Med Sci  2020,20(2),218-225","journal-title":"Bosn J Basic Med Sci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1186\/s12885-016-2837-5","volume":"16","author":"Fenger J.M.","year":"2016","unstructured":"Fenger J.M.; Roberts R.D.; Iwenofu O.H.; MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines. BMC Cancer  2016,16(1),784","journal-title":"BMC Cancer"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/cancers11010007","volume":"11","author":"Wang N.","year":"2018","unstructured":"Wang N.; Tan H.Y.; Feng Y.G.; Zhang C.; Chen F.; Feng Y.; microRNA-23a in human cancer: Its roles, mechanisms and therapeutic relevance. Cancers (Basel)  2018,11(1),7","journal-title":"Cancers (Basel)"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1159\/000366353","volume":"34","author":"He Y.","year":"2014","unstructured":"He Y.; Meng C.; Shao Z.; Wang H.; Yang S.; MiR-23a functions as a tumor suppressor in osteosarcoma. Cell Physiol Biochem  2014,34(5),1485-1496","journal-title":"Cell Physiol Biochem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1089\/cbr.2019.2939","volume":"34","author":"Wang J.","year":"2019","unstructured":"Wang J.; Liu S.; Shi J.; The role of miRNA in the diagnosis, prognosis, and treatment of osteosarcoma. Cancer Biother Radiopharm  2019,34(10),605-613","journal-title":"Cancer Biother Radiopharm"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fped.2015.00069","volume":"3","author":"Sampson V.B.","year":"2015","unstructured":"Sampson V.B.; Yoo S.; Kumar A.; Vetter N.S.; Kolb E.A.; MicroRNAs and potential targets in osteosarcoma. Front Pediatr  2015,3,69","journal-title":"Front Pediatr"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"8687","DOI":"10.3892\/ol.2018.8397","volume":"15","author":"Li Z.","year":"2018","unstructured":"Li Z.; Ni J.; Song D.; Ding M.; Regulatory mechanism of microRNA 128 in osteosarcoma tumorigenesis and evolution through targeting SASH1. Oncol Lett  2018,15(6),8687-8694","journal-title":"Oncol Lett"},{"key":"ref=72","first-page":"2989","volume":"21","author":"Hua Y.","year":"2017","unstructured":"Hua Y.; Jin Z.; Zhou F.; Zhang Y.Q.; Zhuang Y.; The expression significance of serum MiR-21 in patients with osteosarcoma and its relationship with chemosensitivity. Eur Rev Med Pharmacol Sci  2017,21(13),2989-2994","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3233\/CBM-150493","volume":"15","author":"Wang T.","year":"2015","unstructured":"Wang T.; Ji F.; Dai Z.; Xie Y.; Yuan D.; Increased expression of microRNA-191 as a potential serum biomarker for diagnosis and prognosis in human osteosarcoma. Cancer Biomark  2015,15(5),543-550","journal-title":"Cancer Biomark"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"6095","DOI":"10.1007\/s13277-015-3290-9","volume":"36","author":"Huang Y.Z.","year":"2015","unstructured":"Huang Y.Z.; Zhang J.; Shao H.Y.; Chen J.P.; Zhao H.Y.; MicroRNA-191 promotes osteosarcoma cells proliferation by targeting checkpoint kinase 2. Tumour Biol  2015,36(8),6095-6101","journal-title":"Tumour Biol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.biopha.2015.07.018","volume":"75","author":"Yang Z.","year":"2015","unstructured":"Yang Z.; Zhang Y.; Zhang X.; Serum microRNA-221 functions as a potential diagnostic and prognostic marker for patients with osteosarcoma. Biomed Pharmacother  2015,75,153-158","journal-title":"Biomed Pharmacother"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3892\/ijmm.2015.2352","volume":"36","author":"Zhu J.","year":"2015","unstructured":"Zhu J.; Liu F.; Wu Q.; Liu X.; miR-221 increases osteosarcoma cell proliferation, invasion and migration partly through the downregulation of PTEN. Int J Mol Med  2015,36(5),1377-1383","journal-title":"Int J Mol Med"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"e53906","DOI":"10.1371\/journal.pone.0053906","volume":"8","author":"Zhao G.","year":"2013","unstructured":"Zhao G.; Cai C.; Yang T.; MicroRNA-221 induces cell survival and cisplatin resistance through PI3K\/Akt pathway in human osteosarcoma. PLoS One  2013,8(1),e53906","journal-title":"PLoS One"},{"key":"ref=78","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317705341","volume":"39","author":"Zhao D.","year":"2017","unstructured":"Zhao D.; Chen Y.; Chen S.; Zheng C.; Hu J.; Luo S.; MiR-19a regulates the cell growth and apoptosis of osteosarcoma stem cells by targeting PTEN. Tumour Biol  2017,39(5)","journal-title":"Tumour Biol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1159\/000356679","volume":"33","author":"Pan W.","year":"2014","unstructured":"Pan W.; Wang H.; Jianwei R.; Ye Z.; MicroRNA-27a promotes proliferation, migration and invasion by targeting MAP2K4 in human osteosarcoma cells. Cell Physiol Biochem  2014,33(2),402-412","journal-title":"Cell Physiol Biochem"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3892\/ijmm.2016.2800","volume":"38","author":"Gao K.","year":"2016","unstructured":"Gao K.; Yin J.; Dong J.; Deregulated WWOX is involved in a negative feedback loop with microRNA-214-3p in osteosarcoma. Int J Mol Med  2016,38(6),1850-1856","journal-title":"Int J Mol Med"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"6261","DOI":"10.3892\/mmr.2015.4197","volume":"12","author":"Liu C.J.","year":"2015","unstructured":"Liu C.J.; Yu K.L.; Liu G.L.; Tian D.H.; miR-214 promotes osteosarcoma tumor growth and metastasis by decreasing the expression of PTEN. Mol Med Rep  2015,12(4),6261-6266","journal-title":"Mol Med Rep"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s10147-019-01433-x","volume":"24","author":"Huang C.","year":"2019","unstructured":"Huang C.; Wang Q.; Ma S.; Sun Y.; Vadamootoo A.S.; Jin C.; A four serum-miRNA panel serves as a potential diagnostic biomarker of osteosarcoma. Int J Clin Oncol  2019,24(8),976-982","journal-title":"Int J Clin Oncol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/abbs\/gmaa034","volume":"52","author":"Gu Z.","year":"2020","unstructured":"Gu Z.; Wu S.; Xu G.; Wu W.; Mao B.; Zhao S.; miR-487a performs oncogenic functions in osteosarcoma by targeting mRNA. Acta Biochim Biophys Sin (Shanghai)  2020,52(6),631-637","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s13577-020-00468-x","volume":"34","author":"Dai J.","year":"2021","unstructured":"Dai J.; Lu L.; Kang L.; Zhang J.; MiR-501-3p promotes osteosarcoma cell proliferation, migration and invasion by targeting BCL7A. Hum Cell  2021,34(2),624-633","journal-title":"Hum Cell"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1159\/000487719","volume":"45","author":"Zhao Y.","year":"2018","unstructured":"Zhao Y.; Xu K.; Liu P.; Post-transcriptional control of angiotensin II type 1 receptor regulates osteosarcoma cell death. Cell Physiol Biochem  2018,45(4),1581-1589","journal-title":"Cell Physiol Biochem"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.biopha.2016.09.108","volume":"84","author":"Wang J.","year":"2016","unstructured":"Wang J.; Wang B.; Chen L.Q.; miR-10b promotes invasion by targeting KLF4 in osteosarcoma cells. Biomed Pharmacother  2016,84,947-953","journal-title":"Biomed Pharmacother"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.3892\/or.2016.4718","volume":"35","author":"Ma C.","year":"2016","unstructured":"Ma C.; Zhan C.; Yuan H.; Cui Y.; Zhang Z.; MicroRNA-603 functions as an oncogene by suppressing BRCC2 protein translation in osteosarcoma. Oncol Rep  2016,35(6),3257-3264","journal-title":"Oncol Rep"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.3892\/mmr.2018.9165","volume":"18","author":"Zhang P.","year":"2018","unstructured":"Zhang P.; Gao H.; Li Q.; Chen X.; Wu X.; Downregulation of microRNA 660 inhibits cell proliferation and invasion in osteosarcoma by directly targeting forkhead box O1. Mol Med Rep  2018,18(2),2433-2440","journal-title":"Mol Med Rep"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"12064","DOI":"10.1007\/s11356-018-1331-9","volume":"25","author":"Xu N.","year":"2018","unstructured":"Xu N.; Yang W.; Liu Y.; Yan F.; Yu Z.; MicroRNA-411 promoted the osteosarcoma progression by suppressing MTSS1 expression. Environ Sci Pollut Res Int  2018,25(12),12064-12071","journal-title":"Environ Sci Pollut Res Int"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10529-017-2445-8","volume":"40","author":"Xie Z.","year":"2018","unstructured":"Xie Z.; Xu J.; Peng L.; Gao Y.; Zhao H.; Qu Y.; miR-149 promotes human osteocarcinoma progression via targeting bone morphogenetic protein 9 (BMP9). Biotechnol Lett  2018,40(1),47-55","journal-title":"Biotechnol Lett"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s13402-016-0288-2","volume":"39","author":"Zhou C.","year":"2016","unstructured":"Zhou C.; Tan W.; Lv H.; Gao F.; Sun J.; Hypoxia-inducible microRNA-488 regulates apoptosis by targeting Bim in osteosarcoma. Cell Oncol (Dordr)  2016,39(5),463-471","journal-title":"Cell Oncol (Dordr)"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.3892\/or.2017.5983","volume":"38","author":"Cai Q.","year":"2017","unstructured":"Cai Q.; Zeng S.; Dai X.; Wu J.; Ma W.; miR-504 promotes tumour growth and metastasis in human osteosarcoma by targeting TP53INP1. Oncol Rep  2017,38(5),2993-3000","journal-title":"Oncol Rep"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.bbrc.2014.01.061","volume":"444","author":"Gao Y.","year":"2014","unstructured":"Gao Y.; Luo L.; Li S.; Yang C.; miR-17 inhibitor suppressed osteosarcoma tumor growth and metastasis via increasing PTEN expression. Biochem Biophys Res Commun  2014,444(2),230-234","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.bbrc.2017.10.002","volume":"495","author":"Sun Z.","year":"2018","unstructured":"Sun Z.; Liu Q.; Hong H.; Zhang H.; Zhang T.; miR-19 promotes osteosarcoma progression by targeting SOCS6. Biochem Biophys Res Commun  2018,495(1),1363-1369","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=95","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317744704","volume":"40","author":"Meng Q.","year":"2018","unstructured":"Meng Q.; Dai M.; Nie X.; MicroRNA-19 contributes to the malignant phenotypes of osteosarcoma in vitro by targeting Pax6. Tumour Biol  2018,40(1)","journal-title":"Tumour Biol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1139\/bcb-2017-0186","volume":"96","author":"Peng N.","year":"2018","unstructured":"Peng N.; Miao Z.; Wang L.; Liu B.; Wang G.; Guo X.; MiR-378 promotes the cell proliferation of osteosarcoma through down-regulating the expression of Kruppel-like factor 9. Biochem Cell Biol  2018,96(5),515-521","journal-title":"Biochem Cell Biol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.gene.2017.01.002","volume":"606","author":"Jiang X.","year":"2017","unstructured":"Jiang X.; Li X.; Wu F.; Overexpression of miR-92a promotes the tumor growth of osteosarcoma by suppressing F-box and WD repeat-containing protein 7. Gene  2017,606,10-16","journal-title":"Gene"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1042\/CS20150509","volume":"130","author":"Zhou Z.","year":"2016","unstructured":"Zhou Z.; Wang Z.; Wei H.; Wu S.; Wang X.; Xiao J.; Promotion of tumour proliferation, migration and invasion by miR-92b in targeting RECK in osteosarcoma. Clin Sci (Lond)  2016,130(11),921-930","journal-title":"Clin Sci (Lond)"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.3892\/or.2015.4242","volume":"34","author":"Yuan H.","year":"2015","unstructured":"Yuan H.; Gao Y.; MicroRNA-1908 is upregulated in human osteosarcoma and regulates cell proliferation and migration by repressing PTEN expression. Oncol Rep  2015,34(5),2706-2714","journal-title":"Oncol Rep"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biopha.2015.08.012","volume":"75","author":"Chen B.","year":"2015","unstructured":"Chen B.; Bao Y.; Chen X.; Mir-664 promotes osteosarcoma cells proliferation via downregulating of FOXO4. Biomed Pharmacother  2015,75,1-7","journal-title":"Biomed Pharmacother"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3233\/CBM-170452","volume":"21","author":"Li Q.C.","year":"2017","unstructured":"Li Q.C.; Xu H.; Wang X.; Wang T.; Wu J.; miR-34a increases cisplatin sensitivity of osteosarcoma cells in vitro through up-regulation of c-Myc and Bim signal. Cancer Biomark  2017,21(1),135-144","journal-title":"Cancer Biomark"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"e30722","DOI":"10.1097\/MD.0000000000030722","volume":"101","author":"Lian H.","year":"2022","unstructured":"Lian H.; Zhou Y.; Sun Z.; Liu K.; MicroRNA34a is associated with chemotherapy resistance, metastasis, recurrence, survival, and prognosis in patient with osteosarcoma. Medicine (Baltimore)  2022,101(38),e30722","journal-title":"Medicine (Baltimore)"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"e10623","DOI":"10.1002\/jbm4.10623","volume":"6","author":"Bae Y.","year":"2022","unstructured":"Bae Y.; Zeng H.C.; Chen Y.T.; miRNA-34c suppresses osteosarcoma progression in vivo by targeting notch and E2F. JBMR Plus  2022,6(5),e10623","journal-title":"JBMR Plus"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fgene.2015.00233","volume":"6","author":"Gindin Y.","year":"2015","unstructured":"Gindin Y.; Jiang Y.; Francis P.; miR-23a impairs bone differentiation in osteosarcoma via down-regulation of GJA1. Front Genet  2015,6,233","journal-title":"Front Genet"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"71","DOI":"10.21873\/cgp.20113","volume":"16","author":"Fujii R.","year":"2019","unstructured":"Fujii R.; Osaka E.; Sato K.; Tokuhashi Y.; MiR-1 suppresses proliferation of osteosarcoma cells by up-regulating p21 via PAX3. Cancer Genomics Proteomics  2019,16(1),71-79","journal-title":"Cancer Genomics Proteomics"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1177\/0300060517734114","volume":"46","author":"Liu W.","year":"2018","unstructured":"Liu W.; Zhao X.; Zhang Y.J.; Fang G.W.; Xue Y.; MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma. J Int Med Res  2018,46(3),975-983","journal-title":"J Int Med Res"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"8579","DOI":"10.1007\/s13277-015-3614-9","volume":"36","author":"Shi Z.","year":"2015","unstructured":"Shi Z.; Chu X.; Wu Y.; MicroRNA-375 functions as a tumor suppressor in osteosarcoma by targeting PIK3CA. Tumour Biol  2015,36(11),8579-8584","journal-title":"Tumour Biol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3233\/CBM-171103","volume":"22","author":"Yao Z.S.","year":"2018","unstructured":"Yao Z.S.; Li C.; Liang D.; Diagnostic and prognostic implications of serum miR-101 in osteosarcoma. Cancer Biomark  2018,22(1),127-133","journal-title":"Cancer Biomark"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"411","DOI":"10.7150\/thno.33482","volume":"10","author":"Zhang K.","year":"2020","unstructured":"Zhang K.; Dong C.; Chen M.; Extracellular vesicle-mediated delivery of miR-101 inhibits lung metastasis in osteosarcoma. Theranostics  2020,10(1),411-425","journal-title":"Theranostics"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"7025","DOI":"10.1007\/s13277-014-1965-2","volume":"35","author":"Guo S.","year":"2014","unstructured":"Guo S.; Bai R.; Liu W.; miR-22 inhibits osteosarcoma cell proliferation and migration by targeting HMGB1 and inhibiting HMGB1-mediated autophagy. Tumour Biol  2014,35(7),7025-7034","journal-title":"Tumour Biol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"7209","DOI":"10.3892\/mmr.2018.8790","volume":"17","author":"Zhou X.","year":"2018","unstructured":"Zhou X.; Natino D.; Zhai X.; Gao Z.; He X.; MicroRNA 22 inhibits the proliferation and migration, and increases the cisplatin sensitivity, of osteosarcoma cells. Mol Med Rep  2018,17(5),7209-7217","journal-title":"Mol Med Rep"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3233\/CBM-170672","volume":"21","author":"Cong C.","year":"2018","unstructured":"Cong C.; Wang W.; Tian J.; Gao T.; Zheng W.; Zhou C.; Identification of serum miR-124 as a biomarker for diagnosis and prognosis in osteosarcoma. Cancer Biomark  2018,21(2),449-454","journal-title":"Cancer Biomark"},{"key":"ref=113","first-page":"545","volume":"39","author":"Yang Z.","year":"2018","unstructured":"Yang Z.; Wa Q.D.; Lu C.; Pan W.; Lu Z.M.; Ao J.; miR 328 3p enhances the radiosensitivity of osteosarcoma and regulates apoptosis and cell viability via H2AX. Oncol Rep  2018,39(2),545-553","journal-title":"Oncol Rep"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"25414","DOI":"10.18632\/oncotarget.11003","volume":"9","author":"Dai N.","year":"2018","unstructured":"Dai N.; Qing Y.; Cun Y.; miR-513a-5p regulates radiosensitivity of osteosarcoma by targeting human apurinic\/apyrimidinic endonuclease. Oncotarget  2018,9(39),25414-25426","journal-title":"Oncotarget"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"9870693","DOI":"10.1155\/2018\/9870693","volume":"2018","author":"Liu Q.","year":"2018","unstructured":"Liu Q.; Song Y.; Duan X.; Chang Y.; Guo J.; MiR-92a inhibits the progress of osteosarcoma cells and increases the cisplatin sensitivity by targeting Notch1. BioMed Res Int  2018,2018,9870693","journal-title":"BioMed Res Int"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"8812","DOI":"10.12659\/MSM.911972","volume":"24","author":"Xu W.","year":"2018","unstructured":"Xu W.; Li Z.; Zhu X.; Xu R.; Xu Y.; miR-29 family inhibits resistance to methotrexate and promotes cell apoptosis by targeting COL3A1 and MCL1 in osteosarcoma. Med Sci Monit  2018,24,8812-8821","journal-title":"Med Sci Monit"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s13238-016-0277-2","volume":"7","author":"Zhu K.","year":"2016","unstructured":"Zhu K.; Liu L.; Zhang J.; MiR-29b suppresses the proliferation and migration of osteosarcoma cells by targeting CDK6. Protein Cell  2016,7(6),434-444","journal-title":"Protein Cell"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3727\/096504016X14719078133401","volume":"25","author":"Zhang M.","year":"2017","unstructured":"Zhang M.; Wang D.; Zhu T.; Yin R.; miR-214-5p targets ROCK1 and suppresses proliferation and invasion of human osteosarcoma cells. Oncol Res  2017,25(1),75-81","journal-title":"Oncol Res"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"e3103","DOI":"10.1038\/cddis.2017.499","volume":"8","author":"Ji Q.","year":"2017","unstructured":"Ji Q.; Xu X.; Li L.; Goodman S.B.; Bi W.; Xu M.; Xu Y.; Fan Z.; Maloney W.J.; Ye Q.; Wang Y.; miR-216a inhibits osteosarcoma cell proliferation, invasion and metastasis by targeting CDK14. Cell Death Dis  2017,8(10),e3103-e3","journal-title":"Cell Death Dis"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.biopha.2015.02.014","volume":"71","author":"Sun B.","year":"2015","unstructured":"Sun B.; Yang M.; Li M.; Wang F.; The microRNA-217 functions as a tumor suppressor and is frequently downregulated in human osteosarcoma. Biomed Pharmacother  2015,71,58-63","journal-title":"Biomed Pharmacother"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.biopha.2015.04.012","volume":"72","author":"Wei R.","year":"2015","unstructured":"Wei R.; Deng Z.; Su J.; miR-217 targeting Wnt5a in osteosarcoma functions as a potential tumor suppressor. Biomed Pharmacother  2015,72,158-164","journal-title":"Biomed Pharmacother"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4103\/0973-1482.191635","volume":"12","author":"Wu H","year":"2016","unstructured":"Wu H; Li W; Zhang M; Zhu S; Zhang D; Wang X.; Inhibitory roles of miR-320 in osteosarcoma via regulating E2F1. J Cancer Res Ther  2016,12,68-71","journal-title":"J Cancer Res Ther"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s13577-018-0215-0","volume":"31","author":"Chen H.","year":"2018","unstructured":"Chen H.; Gao S.; Cheng C.; MiR-323a-3p suppressed the glycolysis of osteosarcoma via targeting LDHA. Hum Cell  2018,31(4),300-309","journal-title":"Hum Cell"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.biopha.2016.10.008","volume":"84","author":"Cao L.","year":"2016","unstructured":"Cao L.; Wang J.; Wang P.Q.; MiR-326 is a diagnostic biomarker and regulates cell survival and apoptosis by targeting Bcl-2 in osteosarcoma. Biomed Pharmacother  2016,84,828-835","journal-title":"Biomed Pharmacother"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1476-4598-9-96","volume":"9","author":"Song B.","year":"2010","unstructured":"Song B.; Wang Y.; Titmus M.A.; Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer  2010,9(1),96","journal-title":"Mol Cancer"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"e83571","DOI":"10.1371\/journal.pone.0083571","volume":"8","author":"Zhao H.","year":"2013","unstructured":"Zhao H.; Li M.; Li L.; Yang X.; Lan G.; Zhang Y.; MiR-133b is down-regulated in human osteosarcoma and inhibits osteosarcoma cells proliferation, migration and invasion, and promotes apoptosis. PLoS One  2013,8(12),e83571","journal-title":"PLoS One"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3892\/ijo.2012.1717","volume":"42","author":"Novello C.","year":"2013","unstructured":"Novello C.; Pazzaglia L.; Cingolani C.; miRNA expression profile in human osteosarcoma: Role of miR-1 and miR-133b in proliferation and cell cycle control. Int J Oncol  2013,42(2),667-675","journal-title":"Int J Oncol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1159\/000343336","volume":"30","author":"Li G.","year":"2012","unstructured":"Li G.; Cai M.; Fu D.; Heat shock protein 90B1 plays an oncogenic role and is a target of microRNA-223 in human osteosarcoma. Cell Physiol Biochem  2012,30(6),1481-1490","journal-title":"Cell Physiol Biochem"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1016\/j.ajpath.2012.02.023","volume":"180","author":"Zhu J.","year":"2012","unstructured":"Zhu J.; Feng Y.; Ke Z.; Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin. Am J Pathol  2012,180(6),2440-2451","journal-title":"Am J Pathol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.3892\/ijmm.2012.1111","volume":"30","author":"Zhao H.","year":"2012","unstructured":"Zhao H.; Guo M.; Zhao G.; miR-183 inhibits the metastasis of osteosarcoma via downregulation of the expression of Ezrin in F5M2 cells. Int J Mol Med  2012,30(5),1013-1020","journal-title":"Int J Mol Med"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1159\/000488612","volume":"46","author":"Zheng Z.","year":"2018","unstructured":"Zheng Z.; Bao F.; Chen X.; Huang H.; Zhang X.; MicroRNA-330-3p expression indicates good prognosis and suppresses cell proliferation by targeting Bmi-1 in osteosarcoma. Cell Physiol Biochem  2018,46(2),442-450","journal-title":"Cell Physiol Biochem"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.3727\/096504017X14886485417426","volume":"25","author":"Zhang S.","year":"2017","unstructured":"Zhang S.; Liu L.; Lv Z.; Li Q.; Gong W.; Wu H.; MicroRNA-342-3p inhibits the proliferation, migration, and invasion of osteosarcoma cells by targeting astrocyte-elevated gene-1 (AEG-1). Oncol Res  2017,25(9),1505-1515","journal-title":"Oncol Res"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.biopha.2017.12.086","volume":"98","author":"Xu Y.","year":"2018","unstructured":"Xu Y.; Chu H.; Zhou Y.; Wang J.; Dong C.; Yin R.; miR-365 functions as a tumor suppressor by directly targeting CYR61 in osteosarcoma. Biomed Pharmacother  2018,98,531-537","journal-title":"Biomed Pharmacother"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1089\/dna.2013.1977","volume":"32","author":"Jin Y.","year":"2013","unstructured":"Jin Y.; Peng D.; Shen Y.; MicroRNA-376c inhibits cell proliferation and invasion in osteosarcoma by targeting to transforming growth factor-alpha. DNA Cell Biol  2013,32(6),302-309","journal-title":"DNA Cell Biol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.3892\/mmr.2018.9344","volume":"18","author":"Zhou G.","year":"2018","unstructured":"Zhou G.; Jiang H.; Ma L.; MicroRNA 376a inhibits cell proliferation and invasion in osteosarcoma via directly targeting SATB1. Mol Med Rep  2018,18(3),3521-3528","journal-title":"Mol Med Rep"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1007\/s13277-014-3034-2","volume":"36","author":"Wang L.","year":"2015","unstructured":"Wang L.; Shao J.; Zhang X.; Xu M.; Zhao J.; microRNA-377 suppresses the proliferation of human osteosarcoma MG-63 cells by targeting CDK6. Tumour Biol  2015,36(5),3911-3917","journal-title":"Tumour Biol"},{"key":"ref=137","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317705751","volume":"39","author":"Jiang Z.","year":"2017","unstructured":"Jiang Z.; Jiang C.; Yu C.; Fang J.; MicroRNA-208b inhibits human osteosarcoma progression by targeting ROR2. Tumour Biol  2017,39(6)","journal-title":"Tumour Biol"},{"key":"ref=138","first-page":"589","volume":"39","author":"Wang Y.","year":"2018","unstructured":"Wang Y.; Sun S.; Xu J.; Luo Y.; Xin Y.; Zhao X.; MicroRNA-381 suppresses the proliferation of osteosarcoma cells through LRH-1\/Wnt\/\u03b2-catenin signaling pathway. Oncol Rep  2018,39(2),589-596","journal-title":"Oncol Rep"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/2211-5463.12177","volume":"7","author":"Zhang J.","year":"2017","unstructured":"Zhang J.; Hou W.; Jia J.; Zhao Y.; Zhao B.; MiR\u2010409\u20103p regulates cell proliferation and tumor growth by targeting E74\u2010like factor 2 in osteosarcoma. FEBS Open Bio  2017,7(3),348-357","journal-title":"FEBS Open Bio"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/CAD.0000000000000614","volume":"29","author":"Yan H.","year":"2018","unstructured":"Yan H.; Zhang B.; Fang C.; Chen L.; miR-340 alleviates chemoresistance of osteosarcoma cells by targeting ZEB1. Anticancer Drugs  2018,29(5),440-448","journal-title":"Anticancer Drugs"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.1002\/jcb.27849","volume":"120","author":"Long X.","year":"2019","unstructured":"Long X.; Lin X.J.; P65\u2010mediated miR\u2010590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild\u2010type p53\u2010induced phosphatase 1. J Cell Biochem  2019,120(4),5652-5665","journal-title":"J Cell Biochem"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1159\/000358718","volume":"33","author":"Xu H.","year":"2014","unstructured":"Xu H.; Liu X.; Zhao J.; Down-regulation of miR-3928 promoted osteosarcoma growth. Cell Physiol Biochem  2014,33(5),1547-1556","journal-title":"Cell Physiol Biochem"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3892\/or.2017.5715","volume":"38","author":"Jiang W.","year":"2017","unstructured":"Jiang W.; Zheng J.; Yu T.; Wang J.; Overexpression of microRNA-495 suppresses the proliferation and invasion and induces the apoptosis of osteosarcoma cells by targeting high-mobility group nucleosome-binding domain 5. Oncol Rep  2017,38(2),1099-1107","journal-title":"Oncol Rep"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.gene.2017.12.028","volume":"645","author":"Ru N.","year":"2018","unstructured":"Ru N.; Zhang F.; Liang J.; MiR-564 is down-regulated in osteosarcoma and inhibits the proliferation of osteosarcoma cells via targeting Akt. Gene  2018,645,163-169","journal-title":"Gene"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ygeno.2020.09.009","volume":"113","author":"Wang W.","year":"2021","unstructured":"Wang W.; Li Y.; Zhi S.; LncRNA-ROR\/microRNA-185-3p\/YAP1 axis exerts function in biological characteristics of osteosarcoma cells. Genomics  2021,113(1),450-461","journal-title":"Genomics"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"118544","DOI":"10.1016\/j.lfs.2020.118544","volume":"262","author":"Wang X.","year":"2020","unstructured":"Wang X.; Li C.; Yao W.; Tian Z.; Liu Z.; Ge H.; MicroRNA-761 suppresses tumor progression in osteosarcoma via negatively regulating ALDH1B1. Life Sci  2020,262,118544","journal-title":"Life Sci"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11010-014-2265-2","volume":"400","author":"Zhao D.","year":"2015","unstructured":"Zhao D.; Jia P.; Wang W.; Zhang G.; VEGF-mediated suppression of cell proliferation and invasion by miR-410 in osteosarcoma. Mol Cell Biochem  2015,400(1-2),87-95","journal-title":"Mol Cell Biochem"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"6949","DOI":"10.1007\/s13277-015-3396-0","volume":"36","author":"Cui S.Q.","year":"2015","unstructured":"Cui S.Q.; Wang H.; MicroRNA-144 inhibits the proliferation, apoptosis, invasion, and migration of osteosarcoma cell line F5M2. Tumour Biol  2015,36(9),6949-6958","journal-title":"Tumour Biol"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.7150\/ijbs.19476","volume":"13","author":"Li Q.","year":"2017","unstructured":"Li Q.; Li H.; Zhao X.; DNA methylation mediated downregulation of miR-449c controls osteosarcoma cell cycle progression by directly targeting oncogene c-Myc. Int J Biol Sci  2017,13(8),1038-1050","journal-title":"Int J Biol Sci"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.3892\/or.2016.5182","volume":"36","author":"Liu M.","year":"2016","unstructured":"Liu M.; Xiusheng H.; Xiao X.; Wang Y.; Overexpression of miR-422a inhibits cell proliferation and invasion, and enhances chemosensitivity in osteosarcoma cells. Oncol Rep  2016,36(6),3371-3378","journal-title":"Oncol Rep"},{"key":"ref=151","first-page":"618","volume":"16","author":"Deng Y.","year":"2017","unstructured":"Deng Y.; Luan F.; Zeng L.; Zhang Y.; Ma K.; MiR-429 suppresses the progression and metastasis of osteosarcoma by targeting ZEB1. EXCLI J  2017,16,618-627","journal-title":"EXCLI J"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.bbrc.2015.04.013","volume":"461","author":"Li Z.","year":"2015","unstructured":"Li Z.; Wu S.; Lv S.; Wang H.; Wang Y.; Guo Q.; Suppression of liver receptor homolog-1 by microRNA-451 represses the proliferation of osteosarcoma cells. Biochem Biophys Res Commun  2015,461(3),450-455","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.biopha.2016.12.121","volume":"87","author":"Liu W.","year":"2017","unstructured":"Liu W.; Liu S.Y.; He Y.B.; MiR-451 suppresses proliferation, migration and promotes apoptosis of the human osteosarcoma by targeting macrophage migration inhibitory factor. Biomed Pharmacother  2017,87,621-627","journal-title":"Biomed Pharmacother"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3892\/ijmm.2017.3046","volume":"40","author":"Song X.","year":"2017","unstructured":"Song X.; Xie Y.; Liu Y.; Shao M.; Yang W.; MicroRNA-492 overexpression exerts suppressive effects on the progression of osteosarcoma by targeting PAK7. Int J Mol Med  2017,40(3),891-897","journal-title":"Int J Mol Med"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1089\/cbr.2017.2268","volume":"32","author":"Sun Z.","year":"2017","unstructured":"Sun Z.; Li A.; Yu Z.; Li X.; Guo X.; Chen R.; MicroRNA-497-5p suppresses tumor cell growth of osteosarcoma by targeting ADP ribosylation factor-like protein 2. Cancer Biother Radiopharm  2017,32(10),371-378","journal-title":"Cancer Biother Radiopharm"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"8627","DOI":"10.3892\/mmr.2017.7709","volume":"16","author":"Yuan W.","year":"2017","unstructured":"Yuan W.; Wang D.; Liu Y.; miR-494 inhibits cell proliferation and metastasis via targeting of CDK6 in osteosarcoma. Mol Med Rep  2017,16(6),8627-8634","journal-title":"Mol Med Rep"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.3892\/ol.2016.4827","volume":"12","author":"Yao J.","year":"2016","unstructured":"Yao J.; Qin L.; Miao S.; Wang X.; Wu X.; Overexpression of miR-506 suppresses proliferation and promotes apoptosis of osteosarcoma cells by targeting astrocyte elevated gene-1. Oncol Lett  2016,12(3),1840-1848","journal-title":"Oncol Lett"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.biopha.2017.08.120","volume":"95","author":"Hu M.","year":"2017","unstructured":"Hu M.; Yuan X.; Liu Y.; IL-1\u03b2-induced NF-\u03baB activation down-regulates miR-506 expression to promotes osteosarcoma cell growth through JAG1. Biomed Pharmacother  2017,95,1147-1155","journal-title":"Biomed Pharmacother"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.3892\/or.2012.1995","volume":"28","author":"Cai C.K.","year":"2012","unstructured":"Cai C.K.; Zhao G.Y.; Tian L.Y.; miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma. Oncol Rep  2012,28(5),1764-1770","journal-title":"Oncol Rep"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.febslet.2013.03.007","volume":"587","author":"Chen L.","year":"2013","unstructured":"Chen L.; Wang Q.; Wang G.; miR\u201016 inhibits cell proliferation by targeting IGF1R and the Raf1\u2013MEK1\/2\u2013ERK1\/2 pathway in osteosarcoma. FEBS Lett  2013,587(9),1366-1372","journal-title":"FEBS Lett"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.3892\/or.2016.4949","volume":"36","author":"Dong J.","year":"2016","unstructured":"Dong J.; Bi B.; Zhang L.; Gao K.; GLIPR1 inhibits the proliferation and induces the differentiation of cancer-initiating cells by regulating miR-16 in osteosarcoma. Oncol Rep  2016,36(3),1585-1591","journal-title":"Oncol Rep"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3892\/ijo.2018.4374","volume":"53","author":"Ding J.","year":"2018","unstructured":"Ding J.; Sha L.; Shen P.; Huang M.; Cai Q.; Li J.; MicroRNA-18a inhibits cell growth and induces apoptosis in osteosarcoma by targeting MED27. Int J Oncol  2018,53(1),329-338","journal-title":"Int J Oncol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.lfs.2017.09.003","volume":"188","author":"Liu K.","year":"2017","unstructured":"Liu K.; Sun X.; Zhang Y.; Liu L.; Yuan Q.; MiR-598: A tumor suppressor with biomarker significance in osteosarcoma. Life Sci  2017,188,141-148","journal-title":"Life Sci"},{"key":"ref=164","first-page":"2005","volume":"17","author":"Luo Z.","year":"2018","unstructured":"Luo Z.; Wu G.; Zhang D.; Liu J.; Ran R.; microRNA 625 targets Yes associated protein 1 to suppress cell proliferation and invasion of osteosarcoma. Mol Med Rep  2018,17(1),2005-2011","journal-title":"Mol Med Rep"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.abb.2013.04.001","volume":"535","author":"Song L.","year":"2013","unstructured":"Song L.; Yang J.; Duan P.; MicroRNA-24 inhibits osteosarcoma cell proliferation both in vitro and in vivo by targeting LPAAT\u03b2. Arch Biochem Biophys  2013,535(2),128-135","journal-title":"Arch Biochem Biophys"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bbrc.2017.02.045","volume":"486","author":"Liu Z.","year":"2017","unstructured":"Liu Z.; Liu Z.; Zhang Y.; Li Y.; Liu B.; Zhang K.; miR-24 represses metastasis of human osteosarcoma cells by targeting Ack1 via AKT\/MMPs pathway. Biochem Biophys Res Commun  2017,486(2),211-217","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"15033","DOI":"10.1038\/boneres.2015.33","volume":"3","author":"Tan X.","year":"2015","unstructured":"Tan X.; Fan S.; Wu W.; Zhang Y.; MicroRNA-26a inhibits osteosarcoma cell proliferation by targeting IGF-1. Bone Res  2015,3(1),15033","journal-title":"Bone Res"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/onc.2016.194","volume":"36","author":"Lu J.","year":"2017","unstructured":"Lu J.; Song G.; Tang Q.; MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1. Oncogene  2017,36(2),231-241","journal-title":"Oncogene"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.3892\/or.2015.3797","volume":"33","author":"Du J.Y.","year":"2015","unstructured":"Du J.Y.; Wang L.F.; Wang Q.; Yu L.D.; miR-26b inhibits proliferation, migration, invasion and apoptosis induction via the downregulation of 6-phosphofructo-2-kinase\/fructose-2,6-bisphosphatase-3 driven glycolysis in osteosarcoma cells. Oncol Rep  2015,33(4),1890-1898","journal-title":"Oncol Rep"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"16872","DOI":"10.4238\/2015.December.14.14","volume":"14","author":"Zheng W.D.","year":"2015","unstructured":"Zheng W.D.; Zhou F.L.; Lin N.; MicroRNA-26b inhibits osteosarcoma cell migration and invasion by down-regulating PFKFB3 expression. Genet Mol Res  2015,14(4),16872-16879","journal-title":"Genet Mol Res"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07357907.2017.1415348","volume":"36","author":"Xiao Y.","year":"2018","unstructured":"Xiao Y.; Zhao Q.; Du B.; Chen H.; Zhou D.Z.; MicroRNA-187 inhibits growth and metastasis of osteosarcoma by downregulating S100A4. Cancer Invest  2018,36(1),1-9","journal-title":"Cancer Invest"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"34678","DOI":"10.18632\/oncotarget.16149","volume":"8","author":"Xiao Q.","year":"2017","unstructured":"Xiao Q.; Yang Y.; An Q.; Qi Y.; MicroRNA-100 suppresses human osteosarcoma cell proliferation and chemo-resistance via ZNRF2. Oncotarget  2017,8(21),34678-34686","journal-title":"Oncotarget"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s13277-013-1146-8","volume":"35","author":"Huang J.","year":"2014","unstructured":"Huang J.; Gao K.; Lin J.; Wang Q.; MicroRNA-100 inhibits osteosarcoma cell proliferation by targeting Cyr61. Tumour Biol  2014,35(2),1095-1100","journal-title":"Tumour Biol"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"NP40","DOI":"10.1177\/1533034615601281","volume":"15","author":"Liu Y.","year":"2016","unstructured":"Liu Y.; Zhu S.T.; Wang X.; MiR-100 inhibits osteosarcoma cell proliferation, migration, and invasion and enhances chemosensitivity by targeting IGFIR. Technol Cancer Res Treat  2016,15(5),NP40-NP48","journal-title":"Technol Cancer Res Treat"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1159\/000481560","volume":"43","author":"Tao T.","year":"2017","unstructured":"Tao T.; Shen Q.; Luo J.; Xu Y.; Liang W.; MicroRNA-125a regulates cell proliferation via directly targeting E2F2 in osteosarcoma. Cell Physiol Biochem  2017,43(2),768-774","journal-title":"Cell Physiol Biochem"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3233\/CBM-170970","volume":"22","author":"Guo T.","year":"2018","unstructured":"Guo T.; Pan G.; MicroRNA-136 functions as a tumor suppressor in osteosarcoma via regulating metadherin. Cancer Biomark  2018,22(1),79-87","journal-title":"Cancer Biomark"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.bbrc.2016.03.040","volume":"472","author":"Zhang S.","year":"2016","unstructured":"Zhang S.; Zhao Y.; Wang L.; MicroRNA-198 inhibited tumorous behaviors of human osteosarcoma through directly targeting ROCK1. Biochem Biophys Res Commun  2016,472(3),557-565","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"6447","DOI":"10.1007\/s13277-015-4527-3","volume":"37","author":"Dong D.","year":"2016","unstructured":"Dong D.; Gong Y.; Zhang D.; Bao H.; Gu G.; miR-874 suppresses the proliferation and metastasis of osteosarcoma by targeting E2F3. Tumour Biol  2016,37(5),6447-6455","journal-title":"Tumour Biol"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"16367","DOI":"10.1007\/s13277-016-5379-1","volume":"37","author":"Wang X.","year":"2016","unstructured":"Wang X.; Liu J.; Tang Y.; Hong L.; Zeng Z.; Tan G.; MicroRNA-638 inhibits cell proliferation by targeting suppress PIM1 expression in human osteosarcoma. Tumour Biol  2016,37(12),16367-16375","journal-title":"Tumour Biol"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11010-014-2195-z","volume":"397","author":"Sun Z.","year":"2014","unstructured":"Sun Z.; Zhang T.; Hong H.; Liu Q.; Zhang H.; miR-202 suppresses proliferation and induces apoptosis of osteosarcoma cells by downregulating Gli2. Mol Cell Biochem  2014,397(1-2),277-283","journal-title":"Mol Cell Biochem"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1002\/1873-3468.12337","volume":"590","author":"Jiang W.","year":"2016","unstructured":"Jiang W.; Liu J.; Xu T.; Yu X.; MiR\u2010329 suppresses osteosarcoma development by downregulating Rab10. FEBS Lett  2016,590(17),2973-2981","journal-title":"FEBS Lett"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.gene.2018.08.078","volume":"679","author":"Wang L.","year":"2018","unstructured":"Wang L.; Hu K.; Chao Y.; MicroRNA-1301 inhibits migration and invasion of osteosarcoma cells by targeting BCL9. Gene  2018,679,100-107","journal-title":"Gene"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1159\/000472380","volume":"41","author":"Fan L.","year":"2017","unstructured":"Fan L.; Zhu C.; Qiu R.; MicroRNA-661 enhances TRAIL or STS induced osteosarcoma cell apoptosis by modulating the expression of cytochrome c1. Cell Physiol Biochem  2017,41(5),1935-1946","journal-title":"Cell Physiol Biochem"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1089\/cbr.2016.1995","volume":"31","author":"Luo Z.","year":"2016","unstructured":"Luo Z.; Li D.; Luo X.; Decreased expression of miR-548c-3p in osteosarcoma contributes to cell proliferation via targeting ITGAV. Cancer Biother Radiopharm  2016,31(5),153-158","journal-title":"Cancer Biother Radiopharm"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41598-017-18739-3","volume":"8","author":"Sun X.","year":"2018","unstructured":"Sun X.; Dai G.; Yu L.; Hu Q.; Chen J.; Guo W.; miR-143-3p inhibits the proliferation, migration and invasion in osteosarcoma by targeting FOSL2. Sci Rep  2018,8(1),606","journal-title":"Sci Rep"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"8875","DOI":"10.18632\/oncotarget.3560","volume":"6","author":"Han K.","year":"2015","unstructured":"Han K.; Chen X.; Bian N.; MicroRNA profiling identifies miR-195 suppresses osteosarcoma cell metastasis by targeting CCND1. Oncotarget  2015,6(11),8875-8889","journal-title":"Oncotarget"},{"key":"ref=187","first-page":"1082","volume":"8","author":"Xing B.","year":"2016","unstructured":"Xing B.; Ren C.; Tumor-suppressive miR-99a inhibits cell proliferation via targeting of TNFAIP8 in osteosarcoma cells. Am J Transl Res  2016,8(2),1082-1090","journal-title":"Am J Transl Res"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.3892\/ol.2016.5214","volume":"12","author":"Liu J.D.","year":"2016","unstructured":"Liu J.D.; Xin Q.; Tao C.S.; Serum miR-300 as a diagnostic and prognostic biomarker in osteosarcoma. Oncol Lett  2016,12(5),3912-3918","journal-title":"Oncol Lett"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.3892\/mmr.2017.7023","volume":"16","author":"Jia J.","year":"2017","unstructured":"Jia J.; Yin P.; Han G.; Xu M.; Wang W.; Bi W.; MicroRNA-300 decreases cell viability, inhibits migration and promotes apoptosis of osteosarcoma cells via downregulation of Twist1. Mol Med Rep  2017,16(3),3613-3618","journal-title":"Mol Med Rep"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"44252","DOI":"10.18632\/oncotarget.10020","volume":"7","author":"Xin M.","year":"2016","unstructured":"Xin M.; Qiao Z.; Li J.; miR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase: Evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer. Oncotarget  2016,7(28),44252-44265","journal-title":"Oncotarget"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"140","DOI":"10.14715\/cmb\/2022.68.1.18","volume":"68","author":"Zhi W.","year":"2022","unstructured":"Zhi W.; Feng Q.; Mingzhu Z.; MiR-140 targets Wnt1 to inhibit the proliferation and enhance drug sensitivity in osteosarcoma cells. Cell Mol Biol  2022,68(1),140-146","journal-title":"Cell Mol Biol"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"2518297","DOI":"10.1155\/2020\/2518297","volume":"2020","author":"Jiang Y.","year":"2020","unstructured":"Jiang Y.; Zhou C.; Gao Q.; FAM64A promotes osteosarcoma cell growth and metastasis and is mediated by miR-493. J Oncol  2020,2020,2518297","journal-title":"J Oncol"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"100482","DOI":"10.1016\/j.jbo.2023.100482","volume":"40","author":"Daher M.","year":"2023","unstructured":"Daher M.; Zalaquett Z.; Chalhoub R.; Molecular and biologic biomarkers of Ewing sarcoma: A systematic review. J Bone Oncol  2023,40,100482","journal-title":"J Bone Oncol"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fonc.2013.00065","volume":"3","author":"Dylla L.","year":"2013","unstructured":"Dylla L.; Moore C.; Jedlicka P.; MicroRNAs in ewing sarcoma. Front Oncol  2013,3,65","journal-title":"Front Oncol"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.3892\/mmr.2018.9365","volume":"18","author":"Lu Q.","year":"2018","unstructured":"Lu Q.; Lu M.; Li D.; Zhang S.; MicroRNA 34b promotes proliferation, migration and invasion of Ewing\u2019s sarcoma cells by downregulating Notch1. Mol Med Rep  2018,18(4),3577-3588","journal-title":"Mol Med Rep"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.3892\/ijo.2016.3379","volume":"48","author":"Kawano M.","year":"2016","unstructured":"Kawano M.; Tanaka K.; Itonaga I.; Iwasaki T.; Tsumura H.; MicroRNA-301a promotes cell proliferation via PTEN targeting in Ewing\u2019s sarcoma cells. Int J Oncol  2016,48(4),1531-1540","journal-title":"Int J Oncol"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1002\/ijc.30909","volume":"141","author":"Satterfield L.","year":"2017","unstructured":"Satterfield L.; Shuck R.; Kurenbekova L.; miR\u2010130b directly targets ARHGAP1 to drive activation of a metastatic CDC42\u2010PAK1\u2010AP1 positive feedback loop in Ewing sarcoma. Int J Cancer  2017,141(10),2062-2075","journal-title":"Int J Cancer"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.3892\/ijo.2017.4155","volume":"51","author":"Kawano M.","year":"2017","unstructured":"Kawano M.; Tanaka K.; Itonaga I.; Iwasaki T.; Tsumura H.; MicroRNA-20b promotes cell proliferation via targeting of TGF-\u03b2 receptor II and upregulates MYC expression in Ewing\u2019s sarcoma cells. Int J Oncol  2017,51(6),1842-1850","journal-title":"Int J Oncol"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1038\/onc.2012.403","volume":"32","author":"Franzetti G-A.","year":"2013","unstructured":"Franzetti G-A.; Laud-Duval K.; Bellanger D.; Stern M-H.; Sastre-Garau X.; Delattre O.; MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor. Oncogene  2013,32(33),3915-3921","journal-title":"Oncogene"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/cpr.12093","volume":"47","author":"Li J.","year":"2014","unstructured":"Li J.; You T.; Jing J.; MiR\u2010125b inhibits cell biological progression of Ewing\u2019s sarcoma by suppressing the PI3K\/Akt signalling pathway. Cell Prolif  2014,47(2),152-160","journal-title":"Cell Prolif"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1475-2867-13-21","volume":"13","author":"Iida K.","year":"2013","unstructured":"Iida K.; Fukushi J.; Matsumoto Y.; miR-125b develops chemoresistance in Ewing sarcoma\/primitive neuroectodermal tumor. Cancer Cell Int  2013,13(1),21","journal-title":"Cancer Cell Int"},{"key":"ref=202","first-page":"7205","volume":"22","author":"Chao L-M.","year":"2018","unstructured":"Chao L-M.; Sun W.; Chen H.; Liu B.Y.; Li P.F.; Zhao D.W.; MicroRNA-31 inhibits osteosarcoma cell proliferation, migration and invasion by targeting PIK3C2A. Eur Rev Med Pharmacol Sci  2018,22(21),7205-7213","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"10274","DOI":"10.18632\/oncotarget.14394","volume":"8","author":"Li Y.","year":"2017","unstructured":"Li Y.; Shao G.; Zhang M.; miR-124 represses the mesenchymal features and suppresses metastasis in Ewing sarcoma. Oncotarget  2017,8(6),10274-10286","journal-title":"Oncotarget"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3892\/ijo.2016.3317","volume":"48","author":"Tanaka K.","year":"2016","unstructured":"Tanaka K.; Kawano M.; Itonaga I.; Tumor suppressive microRNA-138 inhibits metastatic potential via the targeting of focal adhesion kinase in Ewing\u2019s sarcoma cells. Int J Oncol  2016,48(3),1135-1144","journal-title":"Int J Oncol"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"BSR20171017","DOI":"10.1042\/BSR20171017","volume":"38","author":"Zhou X.","year":"2018","unstructured":"Zhou X.; Chen J.; Xiao Q.; MicroRNA-638 inhibits cell growth and tubule formation by suppressing VEGFA expression in human Ewing sarcoma cells. Biosci Rep  2018,38(1),BSR20171017","journal-title":"Biosci Rep"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"7967","DOI":"10.2147\/OTT.S167771","volume":"11","author":"Zhang S","year":"2018","unstructured":"Zhang S; Li D; Jiao GJ; Wang HL; Yan TB; miR-185 suppresses progression of Ewing's sarcoma via inhibiting the PI3K\/AKT and Wnt\/\u03b2-catenin pathways. Onco Targets Ther  2018,11,7967-7977","journal-title":"Onco Targets Ther"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s13577-017-0183-9","volume":"31","author":"Chen J.","year":"2018","unstructured":"Chen J.; Zhou X.; Xiao Q.; MiR-107 suppresses cell proliferation and tube formation of Ewing sarcoma cells partly by targeting HIF-1\u03b2. Hum Cell  2018,31(1),42-49","journal-title":"Hum Cell"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3892\/ol.2020.12394","volume":"21","author":"Ye C.","year":"2021","unstructured":"Ye C.; Yu X.; Liu X.; Dai M.; Zhang B.; miR-30d inhibits cell biological progression of Ewing\u2019s sarcoma by suppressing the MEK\/ERK and PI3K\/Akt pathways in vitro. Oncol Lett  2021,21(2),133","journal-title":"Oncol Lett"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"e0178028","DOI":"10.1371\/journal.pone.0178028","volume":"12","author":"Moore C.","year":"2017","unstructured":"Moore C.; Parrish J.K.; Jedlicka P.; MiR-193b, downregulated in Ewing Sarcoma, targets the ErbB4 oncogene to inhibit anchorage-independent growth. PLoS One  2017,12(5),e0178028","journal-title":"PLoS One"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s13238-013-3092-z","volume":"4","author":"Liu Y.","year":"2013","unstructured":"Liu Y.; Zhao L.; Li D.; Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development. Protein Cell  2013,4(12),932-941","journal-title":"Protein Cell"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"258","DOI":"10.18632\/oncotarget.2724","volume":"6","author":"Tsai C.H.","year":"2015","unstructured":"Tsai C.H.; Tsai H.C.; Huang H.N.; Resistin promotes tumor metastasis by down-regulation of miR-519d through the AMPK\/p38 signaling pathway in human chondrosarcoma cells. Oncotarget  2015,6(1),258-270","journal-title":"Oncotarget"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"5933","DOI":"10.1007\/s13277-015-4454-3","volume":"37","author":"Jiang D.","year":"2016","unstructured":"Jiang D.; Zheng X.; Shan W.; Shan Y.; The overexpression of miR-30a affects cell proliferation of chondrosarcoma via targeting Runx2. Tumour Biol  2016,37(5),5933-5940","journal-title":"Tumour Biol"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1007\/s13277-014-3026-2","volume":"36","author":"Lu N.","year":"2015","unstructured":"Lu N.; Lin T.; Wang L.; Association of SOX4 regulated by tumor suppressor miR-30a with poor prognosis in low-grade chondrosarcoma. Tumour Biol  2015,36(5),3843-3852","journal-title":"Tumour Biol"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3892\/ijo.2013.2155","volume":"44","author":"Liang W.","year":"2014","unstructured":"Liang W.; Li X.; Li Y.; Gallic acid induces apoptosis and inhibits cell migration by upregulating miR-518b in SW1353 human chondrosarcoma cells. Int J Oncol  2014,44(1),91-98","journal-title":"Int J Oncol"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"28647","DOI":"10.1038\/srep28647","volume":"6","author":"Yang W.H.","year":"2016","unstructured":"Yang W.H.; Chang A.C.; Wang S.W.; Leptin promotes VEGF-C production and induces lymphangiogenesis by suppressing miR-27b in human chondrosarcoma cells. Sci Rep  2016,6(1),28647","journal-title":"Sci Rep"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"917","DOI":"10.7314\/APJCP.2014.15.2.917","volume":"15","author":"Zhu Z.","year":"2014","unstructured":"Zhu Z.; Wang C.P.; Zhang Y.F.; Nie L.; MicroRNA-100 resensitizes resistant chondrosarcoma cells to cisplatin through direct targeting of mTOR. Asian Pac J Cancer Prev  2014,15(2),917-923","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3233\/CBM-160102","volume":"18","author":"Huang K.","year":"2017","unstructured":"Huang K.; Chen J.; Yang M.S.; Tang Y.J.; Pan F.; Inhibition of Src by microRNA-23b increases the cisplatin sensitivity of chondrosarcoma cells. Cancer Biomark  2017,18(3),231-239","journal-title":"Cancer Biomark"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.bcp.2018.05.001","volume":"154","author":"Su C.M.","year":"2018","unstructured":"Su C.M.; Tang C.H.; Chi M.J.; Resistin facilitates VEGF-C-associated lymphangiogenesis by inhibiting miR-186 in human chondrosarcoma cells. Biochem Pharmacol  2018,154,234-242","journal-title":"Biochem Pharmacol"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41419-018-1241-2","volume":"10","author":"Chen S.S.","year":"2019","unstructured":"Chen S.S.; Tang C.H.; Chie M.J.; Resistin facilitates VEGF-A-dependent angiogenesis by inhibiting miR-16-5p in human chondrosarcoma cells. Cell Death Dis  2019,10(1),31","journal-title":"Cell Death Dis"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2147\/DDDT.S90530","volume":"10","author":"Tang XY","year":"2016","unstructured":"Tang XY; Zheng W; Ding M; miR-125b acts as a tumor suppressor in chondrosarcoma cells by the sensitization to doxorubicin through direct targeting the ErbB2-regulated glucose metabolism. Drug Des Devel Ther  2016,10,571-83","journal-title":"Drug Des Devel Ther"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.intimp.2014.06.029","volume":"22","author":"Tan T.W.","year":"2014","unstructured":"Tan T.W.; Chou Y.E.; Yang W.H.; Hsu C.J.; Fong Y.C.; Tang C.H.; Naringin suppress chondrosarcoma migration through inhibition vascular adhesion molecule-1 expression by modulating miR-126. Int Immunopharmacol  2014,22(1),107-114","journal-title":"Int Immunopharmacol"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.canlet.2016.10.010","volume":"385","author":"Wang C.Q.","year":"2017","unstructured":"Wang C.Q.; Huang Y.W.; Wang S.W.; Amphiregulin enhances VEGF-A production in human chondrosarcoma cells and promotes angiogenesis by inhibiting miR-206 via FAK\/c-Src\/PKC\u03b4 pathway. Cancer Lett  2017,385,261-270","journal-title":"Cancer Lett"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/s41419-021-04392-2","volume":"12","author":"Tzeng H.E.","year":"2021","unstructured":"Tzeng H.E.; Lin S.L.; Thadevoos L.A.; Nerve growth factor promotes lysyl oxidase-dependent chondrosarcoma cell metastasis by suppressing miR-149-5p synthesis. Cell Death Dis  2021,12(12),1101","journal-title":"Cell Death Dis"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/jbmr.3976","volume":"35","author":"Urdinez J.","year":"2020","unstructured":"Urdinez J.; Boro A.; Mazumdar A.; The miR\u2010143\/145 cluster, a novel diagnostic biomarker in chondrosarcoma, acts as a tumor suppressor and directly inhibits Fascin\u20101. J Bone Miner Res  2020,35(6),1077-1091","journal-title":"J Bone Miner Res"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/jcb.24940","volume":"116","author":"Mak I.W.Y.","year":"2015","unstructured":"Mak I.W.Y.; Singh S.; Turcotte R.; Ghert M.; The epigenetic regulation of SOX9 by miR-145 in human chondrosarcoma. J Cell Biochem  2015,116(1),37-44","journal-title":"J Cell Biochem"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1074\/jbc.M111.302430","volume":"287","author":"Martinez-Sanchez A.","year":"2012","unstructured":"Martinez-Sanchez A.; Dudek K.A.; Murphy C.L.; Regulation of human chondrocyte function through direct inhibition of cartilage master regulator SOX9 by microRNA-145 (miRNA-145). J Biol Chem  2012,287(2),916-924","journal-title":"J Biol Chem"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.cell.2009.04.059","volume":"137","author":"Chivukula R.R.","year":"2009","unstructured":"Chivukula R.R.; Mendell J.T.; Abate and switch: miR-145 in stem cell differentiation. Cell  2009,137(4),606-608","journal-title":"Cell"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"36896","DOI":"10.18632\/oncotarget.9213","volume":"7","author":"Wang L.H.","year":"2016","unstructured":"Wang L.H.; Lin C.Y.; Liu S.C.; CCL5 promotes VEGF-C production and induces lymphangiogenesis by suppressing miR-507 in human chondrosarcoma cells. Oncotarget  2016,7(24),36896-36908","journal-title":"Oncotarget"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.canlet.2014.11.015","volume":"357","author":"Liu G.T.","year":"2015","unstructured":"Liu G.T.; Huang Y.L.; Tzeng H.E.; Tsai C.H.; Wang S.W.; Tang C.H.; CCL5 promotes vascular endothelial growth factor expression and induces angiogenesis by down-regulating miR-199a in human chondrosarcoma cells. Cancer Lett  2015,357(2),476-487","journal-title":"Cancer Lett"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"e2605","DOI":"10.1038\/cddis.2017.31","volume":"8","author":"Bao X.","year":"2017","unstructured":"Bao X.; Ren T.; Huang Y.; Knockdown of long non-coding RNA HOTAIR increases miR-454-3p by targeting Stat3 and Atg12 to inhibit chondrosarcoma growth. Cell Death Dis  2017,8(2),e2605","journal-title":"Cell Death Dis"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"5590","DOI":"10.3390\/ijms22115590","volume":"22","author":"Veys C.","year":"2021","unstructured":"Veys C.; Benmoussa A.; Contentin R.; Tumor suppressive role of miR-342-5p in human chondrosarcoma cells and 3D organoids. Int J Mol Sci  2021,22(11),5590","journal-title":"Int J Mol Sci"}],"container-title":["MicroRNA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0122115366298799240625115843","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/231939\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0122115366298799240625115843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T06:24:20Z","timestamp":1731047060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/231939\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":231,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0122115366298799240625115843","relation":{},"ISSN":["2211-5366"],"issn-type":[{"type":"print","value":"2211-5366"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}